Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13701209 | 0.90 | HTT (0.67) | L3MBTL1MAPK1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL24296561 | 0.81 | L3MBTL1 (0.63) | L3MBTL1MAPK1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL30141079 | 0.80 | HPGD (0.57) | L3MBTL1MAPK1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL24983859 | 0.80 | HPGD (0.57) | L3MBTL1MAPK1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL6662121 | 0.80 | KMT2A (0.76) | L3MBTL1MAPK1KMT2ASLC6A3MAPT | |
| SCHEMBL14922058 | 0.80 | L3MBTL1 (0.52) | L3MBTL1MAPK1HTTSMN1; SMN2PDE4D | |
| SCHEMBL29317291 | 0.80 | KMT2A (0.53) | L3MBTL1MAPK1KMT2ASMN1; SMN2SLC6A3 | |
| SCHEMBL7945249 | 0.80 | ESR2 (0.57) | L3MBTL1MAPK1KMT2ASMN1; SMN2SLC6A3 | |
| SCHEMBL22014371 | 0.79 | KMT2A (0.60) | L3MBTL1MAPK1KMT2AHTTSLC6A3 | |
| SCHEMBL393566 | 0.79 | MAPK1 (0.50) | L3MBTL1MAPK1KMT2AHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239834-A1 | ALKOXYPHENYL DERIVATIVES, PROTECTED NUCLEOSIDES AND PROTECTED NUCLEOTIDES, METHOD FOR PRODUCING OLIGONUCLEOTIDES, AND METHOD FOR REMOVING SUBSTITUENTS | FUJIMOTO CHEMICALS CO., LTD., (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20210317159-A1 | ALKOXYPHENYL DERIVATIVES, PROTECTED NUCLEOSIDES AND PROTECTED NUCLEOTIDES, METHOD FOR PRODUCING OLIGONUCLEOTIDES, AND METHOD FOR REMOVING SUBSTITUENTS | FUJIMOTO CHEMICALS CO., LTD. (JP) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239834-A1 | ALKOXYPHENYL DERIVATIVES, PROTECTED NUCLEOSIDES AND PROTECTED NUCLEOTIDES, METHOD FOR PRODUCING OLIGONUCLEOTIDES, AND METHOD FOR REMOVING SUBSTITUENTS | ROS1, POLN, RNMT | L3MBTL1 425/4885MAPK1 1144/4885KMT2A 1962/4885 |
| US-20210317159-A1 | ALKOXYPHENYL DERIVATIVES, PROTECTED NUCLEOSIDES AND PROTECTED NUCLEOTIDES, METHOD FOR PRODUCING OLIGONUCLEOTIDES, AND METHOD FOR REMOVING SUBSTITUENTS | ROS1, POLN, RNMT | L3MBTL1 425/4885MAPK1 1144/4885KMT2A 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.